PAGLIARI, MARIA TERESA
PAGLIARI, MARIA TERESA
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
Evaluation of different platelet-dependent von Willebrand factor activity assays to assess the in vivo inhibitory effect of caplacizumab on the von Willebrand factor–platelet interaction
2025 P. Colpani, L. Baronciani, I. Mancini, C. Novembrino, A. Lecchi, G. Cozzi, P. De Leo, M.B. Anzoletti, S. La Marca, M. Boscarino, M.T. Pagliari, A. Artoni, F. Peyvandi
Effect of the Polymorphic Variant p.D1472H on the Platelet‐Dependent VWF Activity Assays
2025 O. Seidizadeh, L. Pati, L. Baronciani, P. Colpani, G. Cozzi, M.T. Pagliari, C. Novembrino, A. Cairo, E. Pappalardo, F. Peyvandi
Type 2M/2A von Willebrand disease: a shared phenotype between type 2M and 2A
2024 O. Seidizadeh, L. Mollica, S. Zambarbieri, L. Baronciani, A. Cairo, P. Colpani, G. Cozzi, M.T. Pagliari, A. Ciavarella, S.M. Siboni, F. Peyvandi
Clinical and Laboratory Presentation and Underlying Mechanism in Patients with Low VWF
2024 O. Seidizadeh, A. Ciavarella, L. Baronciani, F. Boggio, F. Ballardini, G. Cozzi, P. Colpani, M.T. Pagliari, C. Novembrino, S.M. Siboni, F. Peyvandi
PATHOPHYSIOLOGY OF VON WILLEBRAND FACTOR IN BLEEDING AND THROMBOSIS
2023 M.T. Pagliari
Genetic determinants of enhanced von Willebrand factor clearance from plasma
2023 O. Seidizadeh, L. Baronciani, M.T. Pagliari, G. Cozzi, P. Colpani, A. Cairo, S.M. Siboni, E. Biguzzi, F. Peyvandi
von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS
2023 M.T. Pagliari, U. Budde, L. Baronciani, P. Eshghi, M. Ahmadinejad, Z. Badiee, M. Baghaipour, O. Benítez Hidalgo, E. Biguzzi, I. Bodó, G. Castaman, J. Goudemand, M. Karimi, B. Keikhaei, R. Lassila, F.W.G. Leebeek, M.F. Lopez Fernandez, R. Marino, J. Oldenburg, I. Peake, C. Santoro, R. Schneppenheim, A. Tiede, G. Toogeh, A. Tosetto, M. Trossaert, H. Yadegari, E.M.K. Zetterberg, P.M. Mannucci, A.B. Federici, J. Eikenboom, F. Peyvandi
Factor V Leiden but not the factor II 20210G>A mutation is a risk factor for premature coronary artery disease: a case-control study in Iran
2023 P. Agosti, I. Mancini, S. Sadeghian, M.T. Pagliari, S.H. Abbasi, H. Pourhosseini, M. Boroumand, M. Lotfi-Tokaldany, E. Pappalardo, A. Maino, F.R. Rosendaal, F. Peyvandi
Erratum to ‘A comparative study in type 2 von Willebrand disease patients using four different platelet-dependent von Willebrand factor assays.’ [Research and Practice in Thrombosis and Haemostasis Volume 7, Issue 3, March 2023, 100139]
2023 P. Colpani, L. Baronciani, F. Stufano, G. Cozzi, M. Boscarino, M.T. Pagliari, E. Biguzzi, F. Peyvandi
Opium as a risk factor for early-onset coronary artery disease: Results from the Milano-Iran (MIran) study
2023 A. Maino, S. Sadeghian, I. Mancini, S.H. Abbasi, H. Poorhosseini, M.A. Boroumand, M. Lotfi-Tokaldany, A. Jalali, M.T. Pagliari, F.R. Rosendaal, F. Peyvandi
Reply to “Comment on: A comparative study in type 2 von Willebrand disease patients using four different platelet-dependent von Willebrand factor assays”
2023 P. Colpani, L. Baronciani, G. Cozzi, M.T. Pagliari, E. Biguzzi, F. Peyvandi
Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study
2022 M.T. Pagliari, F.R. Rosendaal, M. Ahmadinejad, Z. Badiee, M. Baghaipour, L. Baronciani, O. Benítez Hidalgo, I. Bodó, U. Budde, G. Castaman, P. Eshghi, J. Goudemand, M. Karimi, B. Keikhaei, R. Lassila, F.W.G. Leebeek, M.F. Lopez Fernandez, P.M. Mannucci, R. Marino, J. Oldenburg, I. Peake, C. Santoro, R. Schneppenheim, A. Tiede, G. Toogeh, A. Tosetto, M. Trossaert, H. Yadegari, E.M.K. Zetterberg, F. Peyvandi, A.B. Federici, J. Eikenboom
The dominant p.Thr274Pro mutation in the von Willebrand factor propeptide causes the von Willebrand disease type 1 phenotype in two unrelated patients
2022 M.T. Pagliari, L. Baronciani, C. Cordiglieri, P. Colpani, G. Cozzi, S.M. Siboni, F. Peyvandi
ADAMTS13 activity, high VWF and FVIII levels in the pathogenesis of deep vein thrombosis
2021 M.T. Pagliari, M. Boscarino, A. Cairo, I. Mancini, I. Martinelli, P. Bucciarelli, F. Rossi, F.R. Rosendaal, F. Peyvandi
Role of ADAMTS13, VWF and F8 genes in deep vein thrombosis
2021 M.T. Pagliari, A. Cairo, M. Boscarino, I. Mancini, E. Pappalardo, P. Bucciarelli, I. Martinelli, F.R. Rosendaal, F. Peyvandi
Factor V Leiden but Not Factor II 20210G>A Is a Risk Factor in a Large Cohort of Iranian Patients with Premature Coronary Artery Disease
2020 I. Mancini, S. Sadeghian, M.T. Pagliari, S.H. Abbasi, H. Poorhosseini, M.A. Boroumand, M. Lotfi-Tokaldany, E. Pappalardo, G. Colombo, F. Tafuri, P. Agosti, F.R. Rosendaal, F. Peyvandi
The ADAMTS13-von Willebrand factor axis in COVID-19 patients
2020 I. Mancini, L. Baronciani, A. Artoni, P. Colpani, M. Biganzoli, G. Cozzi, C. Novembrino, M. Boscolo Anzoletti, V. De Zan, M.T. Pagliari, R. Gualtierotti, S. Aliberti, M. Panigada, G. Grasselli, F. Blasi, F. Peyvandi
Evaluation of a fully automated von Willebrand factor assay panel for the diagnosis of von Willebrand disease
2020 F. Stufano, L. Baronciani, P. Bucciarelli, M. Boscarino, P. Colpani, M.T. Pagliari, F. Peyvandi
Factor V Leiden but not factor II 20210G>A is a risk factor in a large cohort of Iranian patients with premature coronary artery disease
2020 I. Mancini, S. Sadeghian, M.T. Pagliari, S.H. Abbasi, H. Poorhosseini, M.A. Boroumand, M. Lotfi-tokaldany, E. Pappalardo, G. Colombo, F. Tafuri, P. Agosti, F.R. Rosendaal, F. Peyvandi
Risk of diagnostic delay in congenital thrombotic thrombocytopenic purpura
2019 B. Ferrari, A. Cairo, M. Pagliari, I. Mancini, S. Arcudi, F. Payvandi